If you've been living with blurry vision and assumed that surgery wasn't on the table for you, this is worth a read. The FDA quietly made a big move in February 2026, expanding the approved age range for EVO ICL (Implantable Collamer Lens) from 21-45 all the way up to 60. That opens the door for millions of Americans who were previously ineligible.
At Clearview Eye and Laser Medical Center, EVO ICL is one of the procedures we're most excited to offer our San Diego patients. So when news like this comes through, we want to make sure you hear about it.
Most people have heard of LASIK, but EVO ICL works on a completely different principle. Instead of using a laser to reshape the cornea, a tiny biocompatible lens is implanted behind the iris and in front of your eye's natural lens. The whole thing is done through a small incision, and no corneal tissue is removed at all.
For patients who have been turned away from LASIK because of thin corneas or a very strong prescription, EVO ICL is often the better path anyway. It corrects nearsightedness from -3.0 D to -20.0 D and handles astigmatism from 1.0 D to 4.0 D, which covers a wide range of prescriptions that LASIK simply can't touch.
One other thing worth knowing: the lens can be removed if your vision needs change down the road. That kind of flexibility is rare in the world of vision correction surgery.
Until now, EVO ICL was only approved in the U.S. for patients between 21 and 45 years old. The new approval stretches that upper limit to 60, bringing the U.S. in line with international markets where older patients have had access to EVO ICL for years.
The expanded approval wasn't just a regulatory formality. It was supported by three years of clinical safety data tracking 629 eyes. The numbers held up well. The safety index came in at 1.25 at the three-year mark, there were zero reported cases of pupillary block or pigment dispersion, and the rate of anterior subcapsular cataract was just 0.16%. Those results matched what researchers have seen in global studies of the EVO platform over the years.
Quite a few. An estimated 24 million American adults are living with myopia that could make them candidates for EVO ICL. Within that group, close to 8 million are between 46 and 60 years old and were simply not eligible before this approval came through.
If someone told you five or ten years ago that surgery wasn't right for you, it's genuinely worth revisiting that conversation. The landscape has shifted.
This approval lines up with a broader trend that's been playing out in refractive surgery over the past few years. A study by the American-European Congress of Ophthalmic Surgery looked at 19 U.S. refractive practices and found that EVO ICL was being used in more than 70% of procedures for patients with prescriptions of -8.0 diopters and above. Surgeons who work with the most challenging prescriptions are increasingly choosing the lens-based approach.
STAAR Surgical, the company behind EVO ICL, recently announced that more than 4 million of these lenses have been sold worldwide. That's not a niche product anymore.
It's worth a conversation if any of the following sound familiar:
One thing to keep in mind: EVO ICL is designed for distance vision. If you're in your late 40s or 50s, you may still need reading glasses for close-up work, which is completely normal and worth discussing with your doctor.
Dr. Sandy T. Feldman and Dr. Michael L. Mathison have been helping San Diego patients see clearly for years, and they'd love to walk you through whether EVO ICL is the right fit for your eyes.
Give us a call at (858) 452-3937 or book your free consultation online. We're open Monday through Saturday and we're happy to answer questions before you ever commit to anything.
EVO ICL is a medical procedure with risks involved and isn't right for everyone. Individual results may vary. Please consult with your eye doctor and consider both the risks and benefits before proceeding. Additional information can be found at evoicl.com or fda.gov.
